Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial

Table 2 Safety summary in the subgroup of women

	Veverimer (n = 46)	Placebo (n = 31)
Deaths	0	0
Serious adverse events	1 (2.2%)	0
Premature discontinuation of study drug due to an adverse event	0	0
Any adverse event	42 (91%)	26 (84%)
Treatment-related adverse event	12 (26%)	13 (42%)

Data are n (%) of patients. The data in this table reflect safety reporting from the subgroup of women patients who received treatment for up to 1 year in both the parent and extension studies

ISSN: 1471-2369